BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

Pulmonx (LUNG)PulmonxConference / presentation

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas

Related news

IARTIntegra LifeSciences2026-11-06 13:00 EST

Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference

TMCITreace Medical Concepts2026-11-03 21:05 EST

Treace to Present at the Stifel 2026 Healthcare Conference

IARTIntegra LifeSciences2026-09-04 13:15 EST

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

ICUIICU Medical2026-11-06 13:30 EST

ICU Medical to Present at the 2026 Jefferies Global Healthcare Conference in London

OMOutset Medical2026-10-27 20:05 EST

Outset Medical to Participate in the 2026 Stifel Healthcare Conference

STXSStereotaxis2026-11-02 13:48 EST

First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT

PLSEPulse Biosciences2026-10-29 17:05 EST

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

LUNGPulmonx2026-10-28 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-10-27 20:05 EST

Pulmonx Reports Third Quarter 2026 Financial Results

ICUSeaStar Medical2026-09-29 12:36 EST

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-10-28 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-10-27 20:05 EST

Pulmonx Reports Third Quarter 2026 Financial Results

LUNGPulmonx2026-10-13 20:05 EST

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

Stock data

Close
2.56 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States